80 ms after the J point for ST-segment depression, using the preceding TP segment as baseline. 15 ST-segment depression of ≥0.5 mm was defined as clinically significant. 15, 16 
Analysis of Biochemical Markers
Blood samples for measurement of plasma CRP and SAA levels were taken on admission. SAA levels were measured by latex-enhanced nephelometric immunoassay, performed on a Hitachi 7600 autoanalyzer (Hitachi, Tokyo, Japan). High-sensitivity CRP levels were simultaneously measured by N Latex CRP Mono tests, performed on a Behring BN II Nephelometer (Behring Diagnostics, Tokyo, Japan) using polystyrene microbeads coated with monoclonal mouse antibodies. 17 In addition, a qualitative assay for cardiac-specific troponin T (TnT; Roche Diagnostics, Tokyo, Japan; detection limit, 0.1 ng/ml of cardiac-specific TnT) was performed. A TnT level of ≥0.1 ng/ml was defined as positive. In patients who were negative within 6 h of the onset of symptoms, the test was repeated at 8-12 h.
Angiographic Analysis
All patients underwent cardiac catheterization a median of 3 days after admission. All coronary angiograms were evaluated by 1 cardiologist who was unaware of all other clinical data. Stenosis ≥75% in any projection was considered clinically significant. In patients with 1 defined culprit lesion, the details of the lesion (morphologic characteristics 18 and presence of thrombus) were examined.
Data Analysis
The study endpoint was a composite of death, myocardial (re)infarction, or refractory angina leading to urgent target-vessel revascularization within 30 days of admission. Myocardial (re)infarction was diagnosed on the basis of either cardiac enzyme levels or ECG evidence. Enzymebased evidence of re-infarction was defined as a re-elevation of the myocardial bound fraction of creatine kinase (CK-MB) to higher than the upper limit of normal if the previous CK-MB level was in the normal range, or 50% above the previous level if the previous level was above the normal range.
Statistical Analysis
Because SAA, CRP, and CK-MB levels do not follow normal distributions, comparisons between groups were carried out using the Mann-Whitney test. The Pearson's correlation analysis was performed to estimate correlations between SAA and CRP. The remaining continuous variables were compared with the use of t-tests. Proportions were compared with the use of chi-squared tests. SAA, CRP, and CK-MB levels are expressed as medians; the remaining variables are expressed as means ± SD. Differences were considered statistically significant at p<0.05. Multiple logistic regression analysis was used to examine determinants of the combined endpoint of death, myocardial (re)infarction, or urgent target-vessel revascularization, because of instability (repeated episodes of angina or hemodynamic instability despite aggressive drug therapy) within 30 days. Variables used for analysis included age, sex, prior infarction, hypertension, diabetes mellitus, TnT, ST-segment depression, and SAA and CRP status on admission. The strength of associations with SAA and CRP was assessed by comparing patients who had normal SAA and CRP levels with those who had elevated levels of SAA, CRP, or both. Odds ratios and 95% confidence inter- 
Results

Baseline Characteristics
Baseline characteristics of the 4 study groups are shown in Table 1 . Patients with both SAA and CRP in the normal range were less likely to have diabetes mellitus, but other baseline characteristics did not differ among the 4 groups. Patients with elevated SAA levels were more likely to have a positive TnT test and higher levels of CK-MB on admission, irrespective of whether or not CRP was elevated. Fig 1 shows the association of SAA and CRP levels on admission.
Angiographic Findings
Culprit vessels were similar in the 4 groups. There was a trend toward a higher incidence of multivessel disease, severe stenosis, and complex culprit lesions in patients who had elevated SAA levels with normal CRP levels, but this did not reach statistical difference.
Clinical Outcomes
Fig 2 shows outcomes at 30 days. Patients with elevated SAA levels had higher rates of adverse events (death, myocardial infarction, or urgent target-vessel revascularization) at 30 days, irrespective of whether CRP was elevated. This relation persisted among the 153 patients who had negative TnT tests. Multivariate analysis showed that positive TnT test, ST-segment depression, and elevated SAA level (groups 3 and 4) were independent predictors of adverse events at 30 days, irrespective of the presence or absence of elevated CRP. In patients with negative TnT tests, ST-segment depression and elevated SAA level (groups 3 and 4) were independent predictors of adverse events at 30 days, irrespective of the presence or absence of elevated CRP levels ( Table 2) .
Discussion
This study showed that elevation of SAA on admission is associated with adverse outcomes at 30 days in patients with NSTE-ACS, irrespective of the presence or absence of elevated CRP levels and, in contrast, elevated CRP levels with normal SAA normal levels were not associated with adverse outcomes at 30 days. These findings suggest that SAA is more strongly related to 30-day outcomes than is CRP alone and may thus provide important prognostic information.
Both CRP and SAA are routinely used clinically as inflammatory markers. These proteins usually respond in parallel to a given stimulus; however, the magnitude of the SAA response has been found to be greater than that of CRP. [8] [9] [10] Some studies have shown that SAA levels increase with higher degrees of inflammation, whereas CRP levels remain normal. 11, 12, 14 Thus, SAA is considered more sensitive and useful than CRP as a marker of acute inflammatory response. [11] [12] [13] [14] There is growing evidence that elevated CRP levels have prognostic value in patients with NSTE-ACS, [4] [5] [6] [7] but data supporting the prognostic value of SAA are more limited. Liuzzo et al reported that elevated SAA on admission was associated with higher rates of revascularization, myocardial infarction, and death in patients with unstable angina without evidence of myocardial necrosis. 7 Morrow et al found that a marked baseline elevation of SAA was predictive of increased mortality at 14 days in patients with unstable angina and non-Q wave myocardial infarction. 19 In those studies, the prognostic roles of SAA and CRP were found to be similar. To our knowledge, however, no previous investigation has assessed the prognostic value of combining the CRP and SAA levels in patients with NSTE-ACS. Our study demonstrated that patients with NSTE-ACS who had elevated SAA levels but normal CRP levels were more likely to have adverse clinical outcomes. Perhaps these patients had low-grade inflammation associated with detectable elevation of SAA, but not of CRP. In contrast, an elevated CRP level with normal SAA level was unrelated to adverse outcomes. Nakayama et al showed that elevated SAA levels tend to disappear more quickly than elevated CRP levels during viral and bacterial infections. 10 Elevated CRP levels with normal SAA levels may thus reflect the early stage of the resolution of inflammation. Because the biosynthesis of SAA and CRP is controlled by different combinations of cytokines, 20 the clinical implications of these proteins to the acute-phase response may differ.
The exact reasons why elevated SAA levels are related to adverse clinical outcomes remain unclear. Myocardial cell necrosis leads to substantial increases in inflammatory markers in NSTE-ACS. However, the relationship between elevated SAA levels and adverse outcomes persisted even among patients with negative TnT tests, suggesting that elevated levels of SAA do not necessary reflect myocardial cell necrosis. SAA has a number of immunomodulatory roles, including induction of chemotaxis of polymorphonuclear cells, monocytes, and T lymphocytes and promotion of the release of tumor necrosis factor-, interleukin (IL)-, and IL-8 from polymorphonuclear cells. 21, 22 SAA can also induce the production of collagenases, which contribute to remodeling of the extracellular matrix in areas of inflammation and weakening of the fibrous cap of plaque, leading to its rupture. 23, 24 CRP has been reported to have similar effects, but differences between CRP and SAA remain unclear. [25] [26] [27] Our study showed a trend toward higher incidences of multivessel disease, severe stenosis, and complex culprit lesions in patients with elevated SAA levels.
Johnson et al showed that SAA levels, but not CRP levels, are related to the severity of coronary artery disease as assessed by coronary angiography in women with a suspected diagnosis of ischemia. 28 The association of elevated SAA levels with adverse outcomes may in part be related to the severity of coronary artery disease. If confirmed in larger studies, our findings have important therapeutic implications because patients with elevated SAA levels at admission are likely to have increased risks of morbidity and mortality, even in the absence of positive TnT tests or elevated CRP levels. Such patients may benefit from more aggressive treatment.
Study Limitations
The results of this study should be considered in the light of following limitations. First, we used strict inclusion entry criteria to ensure a homogeneous group of patients. Therefore, our study group was small. Second, the frequencies of myocardial (re)infarction and mortality at 30 days were low. The differences between patients with and without elevated SAA in the composite endpoint (including death, myocardial (re)infarction, and urgent target-vessel revascularization) resulted from the higher frequency of urgent target-vessel revascularization in the former group. However, the performance of urgent target-vessel revascularization in patients who had refractory angina despite aggressive drug therapy may decrease the frequency of myocardial (re)infarction and mortality. Third, we did not measure the levels of TnT in all patients.
